GHR partners Eli Lilly and Brigham and Women's Hospital announced results from the A4 Study, a landmark in Alzheimer’s Disease research as the first large-scale clinical trial testing an Alzheimer’s prevention strategy in the general population. Unfortunately, A4 was not successful in preventing cognitive decline due to Alzheimer’s Disease.
Funded by a public-private-philanthropic partnership involving the National Institutes of Aging (part of National Institutes of Health), Eli Lilly and Company, Alzheimer’s Association, GHR Foundation, Foundation for the National Institutes of Health, and several other organizations and donors, A4 was a massive ten-year undertaking. It involved dozens of research sites, hundreds of investigators, and thousands of patient volunteers. The study screened healthy adults aged 65-85 for the presence of amyloid plaques. Those with accumulated plaques were treated with Lilly’s anti-amyloid drug solanezumab.
Although the study did not achieve its goal, A4 is providing key learnings for future prevention trials about how to identify patients at risk, when to intervene, and what level of treatment may be needed.
Read the full press release here.
Funded by a public-private-philanthropic partnership involving the National Institutes of Aging (part of National Institutes of Health), Eli Lilly and Company, Alzheimer’s Association, GHR Foundation, Foundation for the National Institutes of Health, and several other organizations and donors, A4 was a massive ten-year undertaking. It involved dozens of research sites, hundreds of investigators, and thousands of patient volunteers. The study screened healthy adults aged 65-85 for the presence of amyloid plaques. Those with accumulated plaques were treated with Lilly’s anti-amyloid drug solanezumab.
Although the study did not achieve its goal, A4 is providing key learnings for future prevention trials about how to identify patients at risk, when to intervene, and what level of treatment may be needed.
Read the full press release here.
RSS Feed
